CL2016000180A1 - Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación - Google Patents

Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación

Info

Publication number
CL2016000180A1
CL2016000180A1 CL2016000180A CL2016000180A CL2016000180A1 CL 2016000180 A1 CL2016000180 A1 CL 2016000180A1 CL 2016000180 A CL2016000180 A CL 2016000180A CL 2016000180 A CL2016000180 A CL 2016000180A CL 2016000180 A1 CL2016000180 A1 CL 2016000180A1
Authority
CL
Chile
Prior art keywords
antituberculous
pyrazinamide
ethambutol
isoniazid
rifampicin
Prior art date
Application number
CL2016000180A
Other languages
English (en)
Inventor
Kumar Amith
Madavan Bindu
Prassad Kum
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51212860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000180A1 publication Critical patent/CL2016000180A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPRIMIDO MONOCAPA PARA EL TRATAMIENTO DE LA TUBERCULOSIS, QUE COMPRENDE A) ISONIAZIDA, PORAZINAMIDA, ETAMBUTOS O UNA SAL DE LOS MISMOS, B) RIFAMPICINA EN POLVO Y C) EXCIPIENTE EXTRAGRANULARES; TAL QUE EL TAMAÑO DE PARTÍCULA ES <0,599NM; PROCESO PARA LA PREPARACIÓN DEL COMPRIMIDO.
CL2016000180A 2013-07-26 2016-01-22 Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación CL2016000180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3343CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
CL2016000180A1 true CL2016000180A1 (es) 2016-06-24

Family

ID=51212860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000180A CL2016000180A1 (es) 2013-07-26 2016-01-22 Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación

Country Status (18)

Country Link
US (1) US9814711B2 (es)
EP (1) EP3024445B1 (es)
JP (1) JP2017501117A (es)
CN (1) CN105407874A (es)
AU (1) AU2014295100B2 (es)
CA (1) CA2918828A1 (es)
CL (1) CL2016000180A1 (es)
HK (1) HK1218721A1 (es)
IL (1) IL243370A0 (es)
MX (1) MX2016001156A (es)
MY (1) MY174007A (es)
PE (1) PE20160238A1 (es)
PH (1) PH12016500118A1 (es)
RU (1) RU2672879C2 (es)
SG (1) SG11201510699WA (es)
TW (1) TW201601716A (es)
WO (1) WO2015011163A1 (es)
ZA (1) ZA201600108B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2694056C2 (ru) 2013-07-26 2019-07-09 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
KR102442586B1 (ko) * 2016-04-08 2022-09-08 큐어테크 바이오 에이비 고리-융합된 티아졸리노 2-피리돈, 이의 제조 방법 및 결핵의 치료 및/또는 예방에 있어서의 그 용도
US11129816B2 (en) * 2017-10-05 2021-09-28 Quretech Bio Ab Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
CN108186638A (zh) * 2018-03-08 2018-06-22 重庆华邦制药有限公司 异烟肼的药物组合物
AU2022405079A1 (en) * 2021-12-07 2024-06-27 An2 Therapeutics, Inc. Combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (zh) 1997-11-26 1999-06-02 岑冠新 复方利福喷丁制剂及制备方法
HUP0203451A3 (en) 2000-08-09 2004-05-28 Panacea Biotec Ltd Pharmaceutical compositions of anti-tubercular drugs and process for their preparation
WO2002087547A1 (en) * 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
RU2195937C1 (ru) * 2002-02-06 2003-01-10 НИИ молекулярной медицины ММА им. И.М.Сеченова Комбинированный противотуберкулезный препарат (ризобутол)
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
EP1711182A1 (en) * 2004-02-04 2006-10-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of antituberculosis drugs
TW201434467A (zh) 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
CN1989966B (zh) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 含利福平和异烟肼的药物组合物
CN1857280A (zh) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 一种复方抗结核药物缓释制剂
KR101197277B1 (ko) 2009-02-05 2012-11-05 (주) 벡스코아 경구용 결핵의 치료용 또는 예방용 고형 제형
WO2011012987A1 (en) 2009-07-31 2011-02-03 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of isoniazid
WO2012013756A2 (fr) * 2010-07-28 2012-02-02 Laboratoires Pharma 5 Procédé de préparation de comprimés contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et éventuellement l'ethambutol
US8470365B2 (en) * 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
WO2015011161A1 (en) 2013-07-26 2015-01-29 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
RU2694056C2 (ru) 2013-07-26 2019-07-09 Санофи Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления

Also Published As

Publication number Publication date
CN105407874A (zh) 2016-03-16
EP3024445B1 (en) 2019-01-09
SG11201510699WA (en) 2016-01-28
AU2014295100A1 (en) 2016-02-11
IL243370A0 (en) 2016-02-29
WO2015011163A1 (en) 2015-01-29
MX2016001156A (es) 2016-04-29
MY174007A (en) 2020-03-03
US9814711B2 (en) 2017-11-14
AU2014295100B2 (en) 2019-01-03
RU2016106336A3 (es) 2018-05-17
HK1218721A1 (zh) 2017-03-10
US20160158226A1 (en) 2016-06-09
RU2672879C2 (ru) 2018-11-20
RU2016106336A (ru) 2017-08-31
ZA201600108B (en) 2017-04-26
TW201601716A (zh) 2016-01-16
EP3024445A1 (en) 2016-06-01
CA2918828A1 (en) 2015-01-29
PH12016500118A1 (en) 2016-04-25
PE20160238A1 (es) 2016-05-05
JP2017501117A (ja) 2017-01-12

Similar Documents

Publication Publication Date Title
CL2016000180A1 (es) Composición antituberculosa que comprende rifampicina, isoniazid, etambutol y pirazinamida y su proceso de preparación
PE20171105A1 (es) Formas solidas de un inhibidor ask1
PH12018501073A1 (en) Eif4-a-inhibiting compounds and methods related thereto
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
CL2016000241A1 (es) Formulación de inhibidores de la syk.
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2015013845A (es) Polvos secos de tiotropio.
NI201800071A (es) Compuestos de isoindol
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
MY183327A (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
IN2014MU00916A (es)
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2019001190A (es) Composicion de liberacion sostenida que comprende tolcapona micronizada.
AR101750A1 (es) Forma sólida de (1-ciano-ciclopropil)amida del ácido (2s,4r)-4-[4-(1-metil-1h-pirazol-4-il)-2-trifluorometil-bencenosulfonil]-1-(1-trifluorometil-ciclopropanocarbonil)pirrolidin-2-carboxílico
AR104622A1 (es) Formas polimorfas de derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores de ido1